BTLA

Class

monoclonal antibody

Notes

original target text: BTLA-targeted monoclonal antibody

B and T lymphocyte attenuator (BTLA) is an inhibitory receptor found on T cells, B cells, and certain myeloid cells. It belongs to the immunoglobulin superfamily, the same family that includes other immune checkpoint receptors, but its binding partner is herpesvirus entry mediator (HVEM), a molecule from a structurally distinct receptor family. When BTLA engages HVEM, it delivers a restraining signal that limits how strongly nearby T cells respond to antigen. This checkpoint helps prevent excessive or self-directed immune activity under normal conditions, but tumors can co-opt it to blunt anti-tumor immune responses, and chronic infections can exploit it to drive T cell exhaustion, a state of reduced immune function. Agents that block BTLA aim to interrupt this inhibitory signal, releasing a brake on T cell activity so that immune cells can respond more effectively against cancer or persistent pathogens. This mechanism is conceptually related to other checkpoint-blocking approaches, such as those targeting PD-1 or CTLA-4, and is being explored primarily in oncology, where restoring suppressed immune surveillance is a central therapeutic goal. BTLA can be targeted by monoclonal antibodies or, as in some newer approaches, small molecules designed to disrupt the BTLA-HVEM interaction.